Royalty Pharma plc Files 8-K for Financial Reporting

Ticker: RPRX · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1802768

Royalty Pharma PLC 8-K Filing Summary
FieldDetail
CompanyRoyalty Pharma PLC (RPRX)
Form Type8-K
Filed DateFeb 11, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Royalty Pharma dropped an 8-K on 2/11 for financial updates.

AI Summary

Royalty Pharma plc filed an 8-K on February 11, 2025, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event.

Why It Matters

This filing serves as an official notification to investors and the public regarding Royalty Pharma's financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine filing for financial reporting and does not appear to contain any new material information or significant events.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific figures within this excerpt.

When was this 8-K filed?

This 8-K was filed on February 11, 2025.

What is the principal executive office address for Royalty Pharma plc?

The principal executive offices are located at 110 East 59th Street, New York, New York, 10022.

What is the company's telephone number?

The company's telephone number is (212) 883-0200.

What is the SIC code for Royalty Pharma plc?

The Standard Industrial Classification (SIC) code for Royalty Pharma plc is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-11 07:38:36

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Royalty Pharma plc, dated February 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: February 11, 2025 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing